Risperidone questioned as dementia first-line treatment

Geriatrics

Volumn 59, Issue 2, 2004, Pages 11-12

  Saxe, Timothy ^a   Finkel, Sanford I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

AGITATION; CEREBROVASCULAR DISEASE; DEMENTIA; DOSE RESPONSE; DRUG SAFETY; ELDERLY CARE; FALLING; FRACTURE; GERIATRIC CARE; HEART ATRIUM FIBRILLATION; HOME CARE; HUMAN; HYPERTENSION; NURSING HOME; PSYCHOSIS; REVIEW; SEDATION; STROKE; TREATMENT PLANNING;

AGED; ANTIPSYCHOTIC AGENTS; DEMENTIA; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 1142310657     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. 2003 Safety alert - Risperdal (risperidone). www.fda.gov/medwatch/SAFETY/2003/risperdal.htm.
2. Finkel SI, Burns A, Cohen G. Behavioral and psychological symptoms of dementia: A clinical and research update. Overview. International Psychogeriatrics 2000; 12(supp 1):13-8.
3. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg, PL, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia on caregivers. Neurology 1999; 53(5):946-55.
4. Greenspan A, Eerdekers M, Mahmoud R. Risk of cerebrovascular adverse events, including mortality, with risperdone in elderly patients. International Psychogeriatrics; 15(2)261; 2003.
5. Katz I, Schneider L, Kosma CM, Rupnow MFT. Risk of falls in patients with dementia: analysis of a randomized, placebo-controlled risperdone trial. International Psychogeriatrics; 15(2)268; 2003.